Medical Device Sales knowledge
Resume:
Matthew Paolucci
*******.********@*****.***
Professional Summary:
More than 25 years in combined financial sales and service, 19 years as a financial advisor at various corporate and independent broker dealers, the remaining years in financial editing and financial website management. Products sold include stocks, bonds, mutual funds, annuities, life and long-term care insurance, with a planning focus on:
(1) Consolidation
(2) Tax minimization
(3) Leverage, maximizing current and future dollars Helped clients save millions in 2008 through use of inverse funds, bonds and other non-correlated investments
General Summary of Qualifications
● In depth knowledge of all financial, insurance, and investment products
● Very familiar with economic trends, fiscal and monetary policy, global financial markets, interest rates.
● Specifically, in-depth knowledge of medical device companies, pharmaceutical companies
● I also do outside research and have industry sources on the products and individual investments I recommend
● Good at making complex products and solutions easy to understand, and enjoy navigating the client/keeping them on task
Specific Product Research/Sales Example:
For almost 3 years, I have kept close watch on a recently-FDA-approved universal hemostat made up of self-assembling peptides. It is biocompatible, non-toxic, does not cause surgical adhesions, no skin sensitization issues, is blood thinner friendly, easy to prepare, significantly safer, and stops bleeding 41% faster than any controls. The FDA approval covers topical indications: Partial and full-thickness wounds, burns, diabetic foot ulcers, venous ulcers, and pressure ulcers. The hemostasis/wound care markets are roughly $40-$50 billion, growing at 10% annually, with this hemostatic device having no real competition.
General Sales Techniques Used:
Personal Relatable Stories
Consistent Test Closes / Confirming Commitment
Numerically Framing to Communicate Features/Benefits/Costs Detail Competitive Advantages of Product/Service
Focus on Strength of IP (if applicable) - Both Initial Patents and Follow-on Patents Emphasize Safety and Efficacy (if product)-Side Effects / Cite Track Record Key on Benefits of Materials Used/Product Improvements Work History
● CUNA Mutual Group/Financial Advisor
Ended: March 1, 2019 Began: 11/01/2016
● American Independent Securities Group/Financial Advisor Ended 10/19/2016
Began: 07/08/2013
● Geneos Wealth Management/Financial Advisor
Ended: 07/05/2013
Began: 08/22/2007
● VALIC Financial Advisors/Financial Advisor
Ended: 8/10/2007
Began: 05/28/2004
● American Express/ IDS Life/Financial Advisor
Ended: 06/03/2004
Began: 12/19/2001
● Premiere Investor Network/ Financial Editor: Financial Websites Ended: 07/01/2001
Began: 05/01/1998
Tools:
● Microsoft Office
● Think or Swim
● Salesforce
Qualifications
In addition to my Bachelor’s degree in Finance and Investments, I have more than 20 years of real-world trading, money management, and financial advisor experience, both as an individual investor and as a Financial Advisor at several broker dealers. I have been buying and selling stocks since high school. I look forward to being that person that complements your team at Fidelity. I absolutely have a passion for the market and helping people. Let me prove it to you.
I am open, and look forward to, any training that will make me a more valuable asset. I hope that my experience helps foster even greater client experience and better results for Fidelity’s clients. I believe that my personal experience and training will be a productive complement to your team.
I get along well with people, I am a team player, I enjoying collaborative discussion, and would love the opportunity to be part of Fidelity, an absolute juggernaut in the investment world. I truly believe that at Fidelity, my true talents can be realized for the benefit of its clients.
My Work History
I have enjoyed various financial positions/roles in my 26 years in the financial services industry, from my start at Janus Funds in the early 1990s, when Tom Bailey was running the firm, Janus was running its first TV commercials for the Janus Mercury Fund during Seinfeld.
But even before this first job at Janus, I was already looking through the Denver Post, as a teenager, trying to swing trade some of the local Colorado companies. Atrix Labs
(ATRX), before they were bought out), Newmont Mining, and Good Times (GTIM) are just a few of the names that come to mind. I have ALWAYS loved individual companies the market overall.
In 1996, after a few years at Janus, I learned about a start-up that had developed a way to send customized emails, funded by paid subscribers, that included stock news
(earnings reports, biotech milestones, management changes, mergers, stock splits, etc.) along with ski reports and other data. It was a true start-up, with ping pong and foosball tables. The company was initially called Infobeat, but was later changed to Exactis Inc. before going public in late 1999. As the Stock Editor there for 3 years, I learned even more about different ways of looking at and researching companies, trading patterns, economic trends, the FED, and taking advantage of the volatility that had started during the later 1990s.
Exactis was a dream job, in my opinion, being in my late 20s. I got paid to watch the market, find the needles in the market haystack, and write articles to educate our subscribers/clients. I did learn some valuable lessons regarding stock options and what a 180 day lock up period can do to if you can’t sell at the right moment. Next, in 1998, trying to learn even more about the markets, I answered an ad in the Denver Post for a Stock Editor at a place called Premiere Investor Network in south Denver. The company ran several financial and trading websites, ranging from stock split-focused, to low-priced stocks, to arbitrage opportunities, to bond strategies, options, special situation stocks, to micro-cap tech and biotech/healthcare plays. It was another chance to gain even more experience. We traded during the day, and wrote market wraps to prepare our subscribers for the next day in the afternoons. As a brain cancer survivor from 1986, biotech, pharmaceuticals, and medical devices had become areas of personal interest and investment interest. I was fascinated with all the breakthroughs, different approaches to cancer and other diseases, and continue watching these trends.
Today, biotech and medtech comprise hundreds of billions of dollars in market size, with some of these sub sectors growing well into the double-double-digits annually. There are daily stories about breakthroughs regarding improvements in patient outcomes, response rates, extending lives, with increased safety and efficacy. I had some of my best trades for subscribers while at Premiere, many in the biotech sector. Many sectors were high-flying during the 90s.
Now, immunotherapy and drug combinations are the way we fight cancer and other diseases. One company i have been following uses electroporation to break apart tumors, administer its combination of IL-2 and Keytruda to stage 3 and 4 cancer patients, and having success. Stage 3 and 4 patients are considered no-hopers. We are truly living in times of great scientific achievement. Another company I have enjoyed watching develop now has an FDA-approved clear gel hemostat/sealant/barrier technology made up of synthetic self-assembling peptides
(amino acid strands), to stop bleeding. The gel is actually classified as a device, not a drug, allowing for a faster, less expensive path to approval. It works much faster than any control, is non-toxic, is non-immunogenic, and helps wounds heal from the inside out. It is like Star Trek technology. With a CE Mark approval expected in 2Q2019, I hope this short example provides a little more color about my love of learning, research, and my passion for finding innovative ways to help clients diversify and succeed. Again, at Premiere, we traded during the day, wrote short news alerts on companies, bullish or bearish, what the technicals looked like (RSI, MACD, Volume, Accumulation/Distribution, support, resistance, chart formations, etc.) and writing market summaries after the close, readying our subscribers for the next day. In 2001, Premiere closed up, laying off everyone, as our subscribers apparently forgot that the market also goes down, even though we showed them how to potentially profit, or at least protect themselves, using inverse funds or buying a long term bonds fund or inverse ETFs.
After Premiere, Investor Network dissolved, I began as a financial at American Express, and that is the role I have enjoyed ever since. Now, I want to join the team at Fidelity.
Contact this candidate